NASDAQ : VERA
Vera Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 30.53 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.20B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.18B |
| Enterprise Value | 1.76B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 72.06M |
| Shares Outstanding | 72.06M |
| Shares Change (YoY) | +12.23% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 92.15% |
| Float | 52.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 20.18 |
| PB Ratio | 5.34 |
| P/TBV Ratio | 5.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.92 |
| Quick Ratio | 10.41 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -55.18 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -91.75% |
| Return on Assets (ROA) | -46.76% |
| Return on Invested Capital (ROIC) | -50.43% |
| Return on Capital Employed (ROCE) | -85.78% |
| Weighted Average Cost of Capital (WACC) | 10.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 361 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +6.29% |
| 50-Day Moving Average | 31.96 |
| 200-Day Moving Average | 36.88 |
| Relative Strength Index (RSI) | 49.80 |
| Average Volume (20 Days) | 1,702,922 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13.59M |
| Short Previous Month | 17.24M |
| Short % of Shares Out | 18.85% |
| Short % of Float | 25.94% |
| Short Ratio (days to cover) | 5.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -415.76M |
| Pretax Income | -401.89M |
| Net Income | -401.90M |
| EBITDA | -415.22M |
| EBIT | -415.76M |
| Earnings Per Share (EPS) | -$5.89 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 499.16M |
| Total Debt | 76.91M |
| Net Cash | 422.26M |
| Net Cash Per Share | $5.86 |
| Equity (Book Value) | 407.76M |
| Book Value Per Share | 5.67 |
| Working Capital | 479.17M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -338.65M |
| Capital Expenditures | -258,000 |
| Depreciation & Amortization | 536,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -338.91M |
| FCF Per Share | -$4.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.23% |
| Shareholder Yield | -12.23% |
| Earnings Yield | -19.48% |
| FCF Yield | -15.55% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $73.79 |
| Price Target Difference | 143.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |